key: cord-0302674-zthms88e authors: Roy-Vallejo, E.; Cardenoso, L.; Triguero-Martinez, A.; Chicot Llano, M.; Zurita Cruz, N. D.; Avalos Perez-Urria, E.; Barrios, A.; Hernando Santos, J.; Ortiz, J.; Rodriguez-Garcia, S. C.; Ciudad Sanudo, M.; Marcos, C.; Garcia Castillo, E.; Fontan Garcia-Rodrigo, L.; Gonzalez, B.; Mendez, R.; Iturrate, I.; Sanz-Garcia, A.; Villa, A.; Sanchez Azofra, A.; Quicios, B.; Arribas, D.; Alvarez-Rodriguez, J.; Patino, P.; Trigueros, M.; Uriarte, M.; Martin Ramirez, A.; Arevalo, C.; Galvan-Roman, J. M.; Garcia-Vicuna, R.; Ancochea, J.; Munoz-Calleja, C.; Fernandez-Ruiz, E.; de la Camara, R.; Fernan, Suarez title: SARS-CoV-2 viremia precedes an IL6 response in severe COVID-19 patients: results of a longitudinal prospective cohort date: 2022-01-24 journal: nan DOI: 10.1101/2022.01.24.22269734 sha: f6086fa9c6a8f4629848fc032830ccd6e699aee7 doc_id: 302674 cord_uid: zthms88e Background: Interleukin 6 (IL6) levels and SARS-CoV-2 viremia have been correlated with COVID-19 severity. The association over time between them has not been assessed in a prospective cohort. Our aim was to evaluate the relationship between SARS-CoV-2 viremia and time evolution of IL6 levels in a COVID-19 prospective cohort. Methods: Secondary analysis from a prospective cohort including COVID-19 hospitalized patients from Hospital Universitario La Princesa between November 2020 and January 2021. Serial plasma samples were collected from admission until discharge. Viral load was quantified by Real-Time Polymerase Chain Reaction and IL6 levels with an enzyme immunoassay. To represent the evolution over time of both variables we used the graphic command twoway of Stata. Results: A total of 57 patients were recruited, with median age of 63 years (IQR [53-81]), 61.4% male and 68.4% caucasian. The peak of viremia appeared shortly after symptom onset in patients with persistent viremia (more than 1 sample with >1.3 log10 copies/ml) and also in those with at least one IL6>30 pg/ml, followed by a progressive increase in IL6 around 10 days later. Persistent viremia in the first week of hospitalization was associated with higher levels of IL6. Both IL6 and SARS-CoV-2 viral load were higher in males, with a quicker increase with age. Conclusions: In those patients with worse outcomes, an early peak of SARS-CoV-2 viral load precedes an increase in IL6 levels. Monitoring SARS-CoV-2 viral load during the first week after symptom onset may be helpful to predict disease severity in COVID-19 patients. One of the most feared complications of the disease caused by the coronavirus SARS-CoV-2 105 (COVID-19), is the development of an Acute Respiratory Distress Syndrome (ARDS), which 106 can affect 15.6-31% of patients [1] . Siddiqui and Mehra [2] proposed that ARDS is part of 107 the final stage of the disease, in which clinical features are mainly the consequence of the 108 host hyperinflammatory response and a cytokine storm; whereas the stage I (early infection) 109 is mainly caused by viral replication and the early immune response. However, to the best of 110 our knowledge, this proposal has not been validated. Since the outbreak of the COVID-19 pandemic, many efforts have been made to find early 113 risk factors and biomarkers able to predict the evolution towards the cytokine storm. In this 114 sense, older age, obesity and comorbidities such as hypertension, diabetes and coronary heart 115 disease have been associated with higher risk of death [3, 4] . On the other hand, increased 116 levels of C reactive protein (CRP), lactate dehydrogenase (LDH) and D-dimer, among others, 117 have been shown to be related to the development of ARDS and mortality [3, 5, 6] . In this context, Interleukin 6 (IL6) has been described as one of the most useful biomarkers 120 [7] . In a previous work, we showed that IL6 could be a severity biomarker but also a guide to 121 select COVID-19 patients who could benefit from treatment with tocilizumab, an inhibitor of 122 the IL6 receptor [8] . Another important biomarker is the presence of SARS-CoV-2 RNA in 123 peripheral blood (viremia), which has been associated with disease severity and a 124 hyperinflammatory state [9,10]. Saji et al. [11] showed that the combination of SpO2/FiO2, 125 IL6 and the presence of SARS-CoV-2 viremia at admission had the highest accuracy to 126 predict fatal outcomes. Bermejo et al. [12] and Myhre et al. [13] found that the presence of 127 SARS-CoV-2 viremia at admission correlated with increased levels of IL6, CRP and ferritin. 128 In addition, a proteomic analysis showed that the expression of viral response and 129 interferon/monocytic pathway proteins such as IL6 and one of its regulators, the In a previous study of our group, we found that viremia was associated with Intensive Care 135 Unit (ICU) admission and in-hospital death, and it was a better biomarker than IL6 [10]. In 150 This work is a secondary analysis of samples from a prospective observational cohort 151 assembled to validate the predictive value of SARS-CoV-2 viremia (ongoing manuscript). . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted January 24, 2022. The study included patients hospitalized for COVID-19 in Hospital Universitario La Princesa 153 (HUP) between November 1st 2020 and January 15th 2021. The inclusion criteria were: a) positive Real-Time Reverse Transcription Polymerase Chain 156 Reaction (rRT-PCR) for SARS-CoV-2 in nasopharyngeal and throat swabs at most 48 hours 157 prior to hospitalization; b) acceptance to participate in the study and oral or written consent; 158 c) age older than 18 years. The exclusion criteria were: a) patients without an initial viremia 159 determination in the first 24-36 hours after admission; b) patients unlikely to be followed-up 160 because they were candidates to be transferred to other health facilities. Clinical, laboratory and therapeutic data were collected from electronic clinical records and 163 included in an anonymized database. Baseline clinical and laboratory data are to those 164 obtained at admission day. The need for hospitalization was decided by the physicians at the emergency room based on 167 clinical criteria, without the intervention of the research team. Patient's treatment and results of the nine wells with 1 copy were omitted because they were widely dispersed. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted January 24, 2022. ; https://doi.org/10.1101/2022.01.24.22269734 doi: medRxiv preprint 5 Viral load was calculated from Ct values using the standard curve as reference and was 204 expressed as copies/ml and the logarithm with base 10 (log10). Due to the variability and lack 205 of accuracy obtained with the lower levels of SARS-CoV-2 viremia, only viremias >1.3 206 log10 (20 copies/ml) were considered quantifiable. Two different variables were used to evaluate IL6 levels: a) a quantitative variable defined as 221 IL6 concentration, expressed in pg/ml, b) a dichotomic variable, which considered levels of 222 IL6 as high when at least one IL6 determination was higher than 30 pg/ml or low if all 223 determinations were below 30 pg/ml. This threshold was based on our previous study, where 224 we showed that IL6>30 pg/ml was associated with poor respiratory outcomes [8]. The Table 1 ). Furthermore, 245 we also applied LOCT strategy for those patients who died or were discharged before the 5 th 246 visit (14 th day after admission), in order to obtain a more homogeneous number of 247 determinations all along the follow-up. To determine which variables were associated with high levels of IL6, we performed a 249 multivariable logistic regression analysis that was first modelled by adding all the variables 250 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 24, 2022. Table 1 ). Most patients who progressed to a severe disease started this evolution 7 to 14 days after the 274 symptoms onset. In addition, patients with a more benign course were discharged at the end 282 The average serum levels of IL6 and SARS-CoV-2 viral load were moderately but 283 significantly correlated (r=0.41, p=0.0014; Supplementary Fig1 ). 284 Figure 1A shows the evolution over time of IL6 and viremia analyzed using data from the 285 whole population (including IL6 after tocilizumab treatment). The peak of viremia appeared 286 early, at the first days after symptom onset (day 3 to 5), and quickly decreased. On the other 287 hand, the highest levels of IL6 were found at day 20. The wide 95% CI suggested a high 288 heterogeineity, specially at both extremes of the time course. Figure 1B shows the results 289 when the LOCF strategy (see Statistical section for further information) was used to 290 minimize the increase of IL6 induced by tocilizumab (see supplementary Figure 2 for raw 291 data in cases treated or not with tocilizumab). With LOCF strategy, the peak of IL6 was 292 smaller, but the time course of IL6 production was quite similar to that obtained from raw 293 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 24, 2022. ; https://doi.org/10.1101/2022.01.24.22269734 doi: medRxiv preprint 7 data. Hereinafter, the relationship between IL6 and SARS-CoV2 viral load shown 294 corresponds to results obtained with the LOCF strategy. 297 A total of 19 patients had high IL6 (Table 1) , of them 11 (57.9%) had persistent viremia 298 compared to 5 patients (13.2%) in the low IL6 group (p=0.001), with an odds ratio of 9.1 299 (95%CI 2.5-32.6) ( Figure 2E ). In the graphic representation of IL6 and viral load according 300 to high/low IL6 (Figure 2A, B) , an early and minor peak of IL6 was found in the low IL6 301 group, together with a small peak of viremia at day 4. On the other hand, patients with at least 302 one IL6 above 30 pg/ml had an early high viremia around day 3 and a progressive increase of 303 IL6 especially after day 12. When the prediction of IL6 and viral load was calculated according to persistent viremia 305 status, remarkable differences were obtained ( Figure 2C, D) . In the persistent viremia group, 306 viral load showed a peak around day 4, whereas IL6 had a two-phase increase: one at the first 307 days from symptom onset and then a subsequent progressive increase after day 5. Regarding The effect of demographic factors on IL6 levels and SARS-CoV-2 viremia was also assessed. The median of the average IL6 concentration was significantly higher in males (11.3 pg/ml However, predicting curves for IL6 and viral load were substantially different depending on 320 sex ( Figure 3A ). In males, curves had a fast increase in viral load with a peak around day 2 321 from symptom onset and a later rise in IL6 levels until day 20, while women showed a small 322 increase in viral load and IL6 between day 2 and 7 approximately. The effect of age on IL6 levels and viral load was also considered. The average levels of IL6 324 and viremia did not correlate with age (r=0.21, p=0.13; and r=0.19, p=0.16; respectively). Moreover, no differences were found when age was categorized as <75 years and >75 years 326 (p=0.57 and p=0.88, for IL6 and viral load respectively). In the group with high IL6, 31.6% 327 of patients were older than 75 years, the same percentage as in the low IL6 group (p=1). Regarding persistent viremia, the proportion of patients older than 75 years was 29.3 % the 329 group with non-persistent viremia and 37.5% in those with persistent viremia (p=0.55). In the 330 prediction curves according to age and sex, all parameters increased with age except for viral 331 load in males, which peaked between 40 and 50 years ( Figure 3B ). with at least one measure of IL6>30 pg/ml, in which it was followed days later by a 346 progressive increase in IL6. Moreover, the presence of persistent viremia in the first week of 347 hospitalization was associated with higher levels of IL6. Both IL6 and SARS-CoV-2 viral 348 load were higher in males, with a progressive increase with age that occurred earlier in males. Our findings are consistent with the COVID-19 phases first described by Siddiqui and Mehra In our previous work [10], we described that the presence of relevant SARS-CoV-2 viremia 358 was associated with higher risk of death and ICU admission. Furthermore, viremia was the 359 most useful biomarker for these outcomes, being superior to IL6, lymphopenia and LDH. In 360 the present study, we show that the SARS-CoV-2 viremia appears early in the course of the 361 disease, standing out as a relevant, simple and early biomarker. Since the beginning of the pandemic, CRP and IL6 levels have not only been used as 364 prognostic biomarkers in COVID-19 but also to guide treatment and predict response to TLR7. This receptor, which recognizes viral single strain RNA and enhances IL6 production, 387 is also located in X chromosome. TLR7 was one of the most important susceptibility genes 388 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 24, 2022. This study has several limitations. First of all, the sample size of our cohort was small, 399 although it was sufficient to find different patterns in the kinetics of IL6 and viral load. The authors declare that the research was conducted in the absence of any commercial or 416 financial relationships that could be construed as a potential conflict of interest. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 24, 2022. ; https://doi.org/10.1101/2022.01.24.22269734 doi: medRxiv preprint study design; in the collection, analysis, and interpretation of data; in the writing of the 436 report; and in the decision to submit the article for publication. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 24, 2022. 582 583 584 585 586 587 588 589 590 591 592 593 594 595 596 597 598 599 600 601 602 603 604 605 606 607 608 609 610 611 612 613 614 615 616 617 618 619 620 621 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 24, 2022. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted January 24, 2022. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted January 24, 2022. ; https://doi.org/10.1101/2022.01.24.22269734 doi: medRxiv preprint Acute respiratory failure in COVID-19: is it "typical COVID-19 Illness in Native and Immunosuppressed States: A 473 Clinical-Therapeutic Staging Proposal Predictors of 476 mortality in hospitalized COVID 19 patients: A systematic review and meta analysis Predictors of 479 COVID 19 severity: A literature review Clinical course and risk factors for 482 mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort 483 study Risk Factors for Severe Disease and 485 Efficacy of Treatment in Patients Infected With COVID-19: A Systematic Review Predictors of in-hospital COVID-19 mortality: A 490 comprehensive systematic review and meta-analysis exploring differences by age, sex 491 and health conditions IL-6 serum levels predict severity and response to 495 Tocilizumab in COVID-19: an observational study Quantitative assessment of SARS CoV 2 RNAemia 498 and outcome in patients with coronavirus disease 2019